XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
3 Months Ended
Mar. 31, 2025
Segment Information  
Segment Information

22.Segment Information

ASU No. 2023-07 Topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about services categories, business segments and major customers in financial statement. The Company manages its business in one reportable operating segment, which is primarily engaged in the manufacturing, marketing, and sales of its patented and FDA cleared product, QuantaFlo. In accordance with Topic 280, the Chief Executive Officer and President has been identified as the Company’s chief operating decision maker (“CODM”), who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The CODM uses segment operating profit to allocate resources including employees, property and investments. The CODM also uses month-over-month expense variance analysis for cost control and for making decisions about allocating capital and personnel to the segment.

The following table breaks out the operations of the Company’s single reportable segment information.

March 31 

March 31 

    

2025

    

2024

Revenue

$

8,835

$

15,903

Less:

Cost of revenue

858

1,127

Research and development (1)

1,306

1,113

Sales

927

1,494

Sales operations

786

784

General and administration

4,873

2,847

Litigation contingency

29,750

Depreciation and amortization

120

176

Other segment expenses (2)

1,316

1,386

Segment operating (loss) profit

(31,101)

6,976

Interest (expense) income, net

(943)

819

Impairment of investments

(1,000)

Change in fair value of digital assets

(41,829)

Other corporate income (3)

4

2

(Loss) income before taxes

(74,869)

7,797

Income tax (benefit) expense

(10,167)

1,724

Net (loss) income

$

(64,702)

$

6,073

1.Research and development expenses include clinical affairs and HITRUST.
2.Other segment expenses include marketing, customer education and business development.
3.Other corporate income represents unallocated income